drug · antibody
ABRILADA
Marketedupdated 3mo agoby $PFE PFIZER INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval190 co-mentions · 88 sources
- drugHUMIRA176 co-mentions · 88 sources
- drugadalimumab156 co-mentions · 88 sources
- drugAMJEVITA81 co-mentions · 81 sources
- drugYUSIMRY81 co-mentions · 81 sources
- company$ABBVAbbVie Inc.61 co-mentions · 61 sources
- drugCYLTEZO24 co-mentions · 12 sources
- drugIDACIO16 co-mentions · 8 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.
targets
Tumor necrosis factor
all catalysts(7)
approval · 7
Nov 15, 2019
approval
$PFE27.79-1.59%
ABRILADA (ADALIMUMAB-AFZB) — FDA approval
ABRILADA
→
Jul 29, 2022
approval
$PFE27.79-1.59%
ABRILADA (ADALIMUMAB-AFZB) — FDA approval
ABRILADA
→
Jun 14, 2023
approval
$PFE27.79-1.59%
ABRILADA (ADALIMUMAB-AFZB) — FDA approval
ABRILADA
→
Aug 16, 2023
approval
$PFE27.79-1.59%
ABRILADA (ADALIMUMAB-AFZB) — FDA approval
ABRILADA
→
Oct 4, 2023
approval
$PFE27.79-1.59%
ABRILADA (ADALIMUMAB-AFZB) — FDA approval
ABRILADA
→
Apr 30, 2024
approval
$PFE27.79-1.59%
ABRILADA (ADALIMUMAB-AFZB) — FDA approval
ABRILADA
→
Dec 17, 2025
approval
$PFE27.79-1.59%
ABRILADA (ADALIMUMAB-AFZB) — FDA approval
ABRILADA
→
News(5)
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 10d ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 20d ago
- cAMPfield lands $180M to build gut disease drugThe biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.biopharma_dive · 2mo ago
- Biogen adds more immune drugs in $1B buyout of secretive startup RayTheraThe companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.biopharma_dive · 2mo ago
- Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.stat · 3mo ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that